Antiviral Platform

Viral infections are highly contagious and therefore widely spread. There are generally two types of viruses: enveloped and non-enveloped. Enveloped viruses cause some of the most severe diseases known in humans, such as Covid-19, influenza, Herpes (HSV-1, HSV-2), Hepatitis B and C, Hemorrhagic Fever (Ebola Virus Disease), and HIV-1 and HIV-2 (the causes of AIDS).

There are general publications indicating a pronounced anti-viral activity of Cinnamon. More specifically, it has been discovered that Cinnovir immediately inhibits viral activity by adhering to the viral envelope or spikes. Thus, it can potentially be applied against a variety of enveloped viruses, to serve as a broad antiviral platform.

Initial studies have been conducted and further studies are warranted. Once the effectiveness of Cinnovir is proven, our solutions will have a broad-spectrum application, including fighting Covid-19, herpes, influenza and several animal viruses.

Schematic Illustration

%title% - Cinnovir inhibits viral activity

Legend:

Left image: the “flowers” symbolize viruses; the large brown arc is the PPF. The graphic depicts attachment of the PPF to the viral envelope/spikes.

Central image: comparison of the two scenarios – the left one, where the unabated viruses have penetrated the host cell of the body, vs. the right one, where PPF is attached to the viral envelope/spikes, thus the virus is “locked” and is unable to penetrate the cell.

Right image: the immune system is identifying and attacking the “locked” virus.

 

Reference List: Scientific and Pre-Clinical Data on Cinnamon Extract Antiviral Properties

  • Premanathan et al. 2000. Indian J Med Res, Sep;112:73-7.
  • Barak, I., Ovadia, M. 2005. “Natural inhibitor of influenzaA-PR8 extracted from cinnamon”. 18th ICAR meeting, April 11-14, 2005, Barcelona, Spain. Antiviral Research Vol 65, A65.
  • Ovadia M. et al. 2006. “Anti Viral Preparation Obtained from a Natural Cinnamon Extract,” USP9364511.
  • Sevillia, G., Kamensky, M., Finger, A., Ovadia, M. 2007. “Cinnamon Extract Inhibits Avian Influenza H9N2 Both in-vitro and in-vivo.” Options for the control of Influenza, p. 467-469.
  • Gueta, K., Kamensky, M., Finger, A., Ovadia, M. 2008. “Immunization against Newcastle Disease Virus Using Cinnamon Fraction.” Annual meeting of Veterinary Institute, Bet-Dagan. Israel Journal of Veterinary Medicine 63(2).
  • Fink, R.C., Roschek, B., Alberte, R.S. 2009. International Medical Press, 2040-2066.
  • Ovadia, M., Kallily, Y., Bernstein, E. 2009. “Cinnamon fraction neutralizes avian influenza H5N1 both in-vitro and in-vivo.” 22nd ICAR meeting, 3-7 May 2009, Miami Beach, Florida. Antiviral Research 82(2), A35.
  • Kallily, I. Kamensky, M. Finger, A. Ovadia, M. 2010. “Immunization against Newcastle disease virus using cinnamon fraction.” Modern Veterinary Vaccines and Adjuvants (MVVA) conference, November 17-19, Budapest, Hungary.
  • Conell, B.J. et al. 2016. “A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation”. PLOS ONE |OI:10.1371/journal.pone.0165386 October 27, 2016.
  • Munazza, F., Zaidi, N.S., Amraiz, D., Afzal F. 2016. “In Vitro Antiviral Activity of Cinnamomum cassia and its Nanoparticles Against H7N3 Influenza A Virus.” Microbiol. Biotechnol. 26(1), 151-159.
  • Kurt, L. et al. 2021. “Cinnamon and Hop Extracts as Potential Immunomodulators for Severe COVID-19 Cases” OPINION ARTICLE Plant Sci., https://doi.org/10.3389/fpls.2021.589783